- Home
- XNCR vs PCN Comparison
XNCR vs PCN Comparison
Compare XNCR & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XNCR | PCN |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 866.4M |
| IPO Year | 2013 | 2001 |
Fundamental Metrics
Financial Performance| Metric | XNCR | PCN |
|---|---|---|
| Price | $11.33 | $11.72 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $22.33 | N/A |
| AVG Volume (30 Days) | ★ 682.9K | 294.6K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $11.40 |
| 52 Week High | $18.69 | $13.49 |
Technical Indicators
Market Signals| Indicator | XNCR | PCN |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 38.42 |
| Support Level | $11.02 | $11.40 |
| Resistance Level | $13.28 | $12.12 |
| Average True Range (ATR) | 0.78 | 0.10 |
| MACD | -0.21 | -0.04 |
| Stochastic Oscillator | 28.45 | 37.48 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.